Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04805970 · ClinicalTrials.gov registry record

REsearching Covid-19 Outcomes in Diabetes (RECODE)

A clinical trial of Diabetes and COVID-19, sponsored by AdventHealth Translational Research Institute.

Active
Registry status
35
Enrollment target
1
Study location

NCT04805970: Active study of Diabetes and COVID-19, sponsored by AdventHealth Translational Research Institute.

NCT04805970 is a study of Diabetes and COVID-19 that is active but no longer recruiting, run by AdventHealth Translational Research Institute. The registered enrollment target is 35 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04805970, a study of Diabetes and COVID-19, is active but no longer recruiting, sponsored by AdventHealth Translational Research Institute.

ACTIVE NOT RECRUITING
Registry status
35 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to observe any changes that may occur to certain organs following a confirmed diagnosis of COVID-19 in people with and without diabetes.

Primary Outcome

Patients recovering from the COVID-19 disease

Conditions Studied

Study Locations (1)

Florida

  • AdventHealth Translational Research Institute - Orlando

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2021-03-24
Est. Completion 2025-12

What the registry record for NCT04805970 still lists

NCT04805970 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 0 interventions.

NCT04805970 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT04805970 about?

NCT04805970 is a clinical study titled "REsearching Covid-19 Outcomes in Diabetes (RECODE)". The purpose of this study is to observe any changes that may occur to certain organs following a confirmed diagnosis of COVID-19 in people with and without diabetes.

What is the current status of trial NCT04805970?

This trial is currently active not recruiting. The enrollment target is 35 participants. The study started on 2021-03-24. Estimated completion is 2025-12.

What conditions does trial NCT04805970 study?

This clinical trial studies the following conditions: Diabetes, COVID-19.

Who is sponsoring clinical trial NCT04805970?

This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04805970 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04805970's enrollment target sits among peer trials

35 273rd of 338 higher than 64 of 338 other Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01697371 · 35 participants · NA

    Proton Therapy in the Treatment of Liver Metastases

  • NCT01940757 · 35 participants · Phase 1

    Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

  • NCT02235857 · 35 participants · NA

    Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

  • NCT02637934 · 35 participants · Phase 1

    Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04805970, the US trial registry maintained by the National Library of Medicine. NCT04805970 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.